NCT00505895 · OUTCOME

Number of Participants With Successful Engraftment at Day 100

FM 140 vs FM100 Study in Patients With Multiple Myeloma · Source last updated 2014-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Day 100

Groups in this outcome

Fludarabine + Melphalan + Stem Cell Infusion

Fludarabine 30 mg/m\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4). Melphalan 140 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5.

Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion

Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 4 Days (Beginning Day -4). Lower-Dose Melphalan 100 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Fludarabine + Melphalan + Stem Cell Infusion	27
Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion	23

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Fludarabine + Melphalan + Stem Cell Infusion	27	Not reported	Not reported	Not reported	Not reported
Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion	23	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
27
group Id
OG001
value
23

denoms

counts
group Id
OG000
value
27
group Id
OG001
value
23
units
Participants

groups

description
Fludarabine 30 mg/m\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4). Melphalan 140 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5.
id
OG000
title
Fludarabine + Melphalan + Stem Cell Infusion
description
Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 4 Days (Beginning Day -4). Lower-Dose Melphalan 100 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5.
id
OG001
title
Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion

param Type

NUMBER

time Frame

Day 100

title

Number of Participants With Successful Engraftment at Day 100

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice